Clinical Trial Update: Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a conditioning regimen of alemtuzumab, fludarabine, and busulfan followed by donor stem cell transplant in young patients with hematolo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Amegakaryocytic Thrombocytopenia
• Congenital Neutropenia
• Diamond-blackfan Anemia
• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• BUSULFAN (Busulfan)
• Donor stem cell transplant
• Fludarabine (Fludarabine)

Snippet

Sponsor: University of California, San Francisco | Conditions: Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia | Phase 2 | Status: COMPLETED | Results posted: 2013-05-16